Karl D. Kieburtz

Neurology

919 Westfall Rd Bldg C
Rochester, NY 14618

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 138 publications

Predicting CSF α-Synuclein Seed Amplification Assay Status From Demographics and Clinical Data.

Predicting CSF α-Synuclein Seed Amplification Assay Status From Demographics and Clinical Data.

Journal: Neurology open access

Published: April 15, 2026

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined Synucleinopathy.

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined Synucleinopathy.

Journal: Annals of clinical and translational neurology

Published: March 13, 2026

Outcomes in Long-Term Follow-Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers Initiative.

Outcomes in Long-Term Follow-Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers Initiative.

Journal: Annals of neurology

Published: March 11, 2026

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease.

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease.

Journal: Annals of neurology

Published: February 09, 2026

Ambroxol for Parkinson's Disease.

Ambroxol for Parkinson's Disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: February 02, 2026

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease.

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease.

Journal: Journal of neurology

Published: December 11, 2025

Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease.

Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease.

Journal: Annals of clinical and translational neurology

Published: September 30, 2025

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.

Journal: Nature aging

Published: June 30, 2025

Polygenic scores for disease risk are not associated with clinical outcomes in Parkinson's disease.

Polygenic scores for disease risk are not associated with clinical outcomes in Parkinson's disease.

Journal: medRxiv : the preprint server for health sciences

Published: February 20, 2025

A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.

A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: January 02, 2025

Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmia.

Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmia.

Journal: medRxiv : the preprint server for health sciences

Published: December 23, 2024

Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder.

Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder.

Journal: Annals of neurology

Published: December 18, 2024

Showing 1-12 of 138

Last Updated: 09/26/2026